Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | FER | P16591 | 6/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CAMK1D | Q8IU85 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946682 | 1.00 | LRRK2 (0.59) | LRRK2FERSLC2A1SRCL3MBTL1 | |
| SCHEMBL12103789 | 0.94 | LRRK2 (0.63) | LRRK2FERSLC2A1SRCL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1299001 | 0.94 | LRRK2 (0.62) | LRRK2FERSLC2A1SRCL3MBTL1 | |
| SCHEMBL12103773 | 0.89 | LRRK2 (0.59) | LRRK2FERSLC2A1CAMK1DJAK2 | |
| Hydrochloric Acid SCHEMBL1298071 | 0.88 | LRRK2 (0.58) | LRRK2FERSLC2A1CAMK1DJAK2 | |
| Hydrochloric Acid SCHEMBL1298076 | 0.88 | LRRK2 (0.58) | LRRK2FERSLC2A1CAMK1DJAK2 | |
| SCHEMBL1298211 | 0.88 | LRRK2 (0.75) | LRRK2FERSLC2A1SRCL3MBTL1 | |
| SCHEMBL12103492 | 0.86 | LRRK2 (0.79) | LRRK2CAMK1D | |
| SCHEMBL12103542 | 0.86 | LRRK2 (0.79) | LRRK2CAMK1D | |
| SCHEMBL1948415 | 0.86 | LRRK2 (0.60) | LRRK2FERSLC2A1SRCL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2330909-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-09-18 | — | — | EP | claimed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2330909-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136838-A1 | CHEMICAL COMPOUNDS | PDK1, PDK4, PDK3 | LRRK2 793/4885FER 576/4885SLC2A1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.